Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook
Rhea-AI Summary
Seer (Nasdaq: SEER) reported fourth-quarter and full-year 2025 results, with $4.2M revenue in Q4 and $16.6M for full year 2025. Installed base grew to 82 instruments (67% YoY) and year-end cash, cash equivalents and investments were approximately $240.6M.
Gross margin was ~51% for 2025, operating expenses fell to $86.5M, and net loss narrowed to $73.6M. Seer expects 2026 revenue of $16M–$18M (midpoint ~3% growth).
Positive
- Installed base grew to 82 instruments, +67% year-over-year
- Full-year revenue increased 17% to $16.6M
- Cash reserve of approximately $240.6M at year-end
Negative
- Net loss of $73.6M for full year 2025
- Operating expenses remained high at $86.5M in 2025
- 2026 revenue guidance implies modest ~3% growth at midpoint
Key Figures
Market Reality Check
Peers on Argus
SEER’s price is unchanged over the last 24 hours while key biotech peers show mixed moves, including declines in ADAG (-5.67%) and KALA (-1.46%) and a gain in IOBT (+1.25%). Only one peer (ARMP) appears in the momentum scanner, reinforcing a stock-specific rather than sector-wide setup.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Positive | -3.2% | Modest revenue growth, reiterated 2025 guidance and strong cash balance. |
| Aug 06 | Q2 2025 earnings | Positive | -2.4% | 32% revenue growth, new high-throughput products, reiterated 2025 outlook. |
| May 13 | Q1 2025 earnings | Positive | +9.9% | 37% revenue growth, lower expenses, strong cash and large new contract. |
| Feb 27 | FY 2024 earnings | Negative | -4.5% | Revenue declines and wider losses despite new applications and buyback. |
| Nov 06 | Q3 2024 earnings | Neutral | +7.3% | Slight revenue decline but solid margin and strategic agreements highlighted. |
Earnings reactions have been mixed: most reports with positive fundamentals saw either sharp gains or selloffs, with both alignments and divergences versus the news tone.
Over the past five earnings cycles, Seer has consistently reported revenue around $4.0–$4.2M per quarter with mid-50% gross margins and substantial but improving operating losses. Prior updates often highlighted revenue growth, cost controls, and a strong cash balance (e.g., $285M in Q1 2025 and $251.2M in Q3 2025) alongside reiterated guidance of $17–$18M for 2025. Today’s 2025 results and 2026 outlook continue that theme of modest top-line growth, improving expenses, and reliance on a sizable cash position.
Historical Comparison
In the last five earnings reports, SEER’s average 1-day move was ±1.39%, with both sharp rallies and selloffs, suggesting earnings have produced uneven trading responses.
Across 2024–2025, Seer maintained quarterly revenue near $4M+, improved operating efficiency, and sustained a large cash balance while reiterating similar annual revenue ranges.
Market Pulse Summary
This announcement details 2025 revenue of $16.6M, up 17% year over year, with a 51% gross margin and a reduced net loss of $73.6M. Seer ended 2025 with $240.6M in cash and investments and guided 2026 revenue to $16–$18M, implying modest growth. Historically, earnings have produced mixed stock reactions, so investors may focus on execution against this outlook, ongoing cost discipline, and the pace of Proteograph instrument and consumable adoption.
AI-generated analysis. Not financial advice.
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Recent Highlights
- Generated revenue of
$4.2 million for the fourth quarter of 2025 and$16.6 million for the full year 2025 - Expanded installed base to 82 instruments, representing
67% year-over-year growth, with 33 total instruments installed during the full year 2025 - Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insight
- Strong presence at the 2025 Human Proteome Organization World Congress with more than a dozen scientific presentations and sixteen posters presented that highlight the translational power of the Proteograph
- Ended the year with approximately
$240.6 million of cash, cash equivalents and investments
“2025 was a challenging year as our customers navigated ongoing budgetary pressures, including uncertainty around NIH funding in the fourth quarter," said Omid Farokhzad, Chair and CEO of Seer. "Despite this persistently challenging funding environment, we made meaningful progress across our business. Our installed base grew significantly, consumable kit volume increased, the number of publications expanded throughout the year, and the Proteograph was selected to power multiple population-scale studies. I am more confident than ever in our opportunities in 2026 and beyond.”
Fourth Quarter 2025 Financial Results
Revenue was
Gross profit was
Operating expenses were
Net loss was
Full Year 2025 Financial Results
Revenue was
Gross profit was
Operating expenses were
Net loss was
Cash, cash equivalents and investments were approximately
2026 Guidance
Seer expects full year 2026 revenue to be in the range of
Webcast Information
Seer will host a conference call to discuss the fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.
About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s expectations for future results of operations and its financial position, business strategy, partnerships, adoption of our products and outlook for fiscal year 2026. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Kelly Gura
investor@seer.bio
Media Contact:
Patrick Schmidt
pr@seer.bio
| SEER, INC. Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue: | |||||||||||||||
| Product | $ | 2,835 | $ | 2,351 | $ | 11,207 | $ | 8,695 | |||||||
| Service | 1,238 | 1,209 | 4,151 | 2,960 | |||||||||||
| Related party | — | 389 | 761 | 2,292 | |||||||||||
| Other | 128 | 51 | 459 | 223 | |||||||||||
| Total revenue | 4,201 | 4,000 | 16,578 | 14,170 | |||||||||||
| Cost of revenue: | |||||||||||||||
| Product | 1,468 | 1,200 | 5,336 | 4,402 | |||||||||||
| Service | 270 | 566 | 1,531 | 1,465 | |||||||||||
| Related party | — | 61 | 224 | 712 | |||||||||||
| Other | 280 | 148 | 1,022 | 536 | |||||||||||
| Total cost of revenue | 2,018 | 1,975 | 8,113 | 7,115 | |||||||||||
| Gross profit | 2,183 | 2,025 | 8,465 | 7,055 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 9,742 | 12,619 | 43,874 | 50,585 | |||||||||||
| Selling, general and administrative | 9,826 | 12,894 | 42,583 | 56,571 | |||||||||||
| Total operating expenses | 19,568 | 25,513 | 86,457 | 107,156 | |||||||||||
| Loss from operations | (17,385 | ) | (23,488 | ) | (77,992 | ) | (100,101 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Interest income | 2,548 | 3,565 | 11,522 | 16,666 | |||||||||||
| Loss on equity method investment | (1,084 | ) | (1,788 | ) | (5,919 | ) | (2,649 | ) | |||||||
| Other income (expense) | (45 | ) | 67 | (1,010 | ) | (417 | ) | ||||||||
| Total other income | 1,419 | 1,844 | 4,593 | 13,600 | |||||||||||
| Loss before provision for income taxes | (15,966 | ) | (21,644 | ) | (73,399 | ) | (86,501 | ) | |||||||
| Provision for income taxes | 28 | 98 | 201 | 98 | |||||||||||
| Net loss | $ | (15,994 | ) | $ | (21,742 | ) | $ | (73,600 | ) | $ | (86,599 | ) | |||
| Net loss per share attributable to Class A and Class B common stockholders, basic and diluted | $ | (0.29 | ) | $ | (0.37 | ) | $ | (1.28 | ) | $ | (1.39 | ) | |||
| Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted | 56,019,318 | 59,091,817 | 57,447,580 | 62,348,012 | |||||||||||
| SEER, INC. Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share amounts) | ||||||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 47,285 | $ | 40,753 | ||||
| Short-term investments | 138,612 | 195,657 | ||||||
| Accounts receivable, net | 4,282 | 3,997 | ||||||
| Related party receivables | 300 | 379 | ||||||
| Other receivables | 1,370 | 1,853 | ||||||
| Inventory | 7,795 | 7,436 | ||||||
| Prepaid expenses and other current assets | 1,890 | 3,248 | ||||||
| Total current assets | 201,534 | 253,323 | ||||||
| Long-term investments | 54,686 | 63,103 | ||||||
| Operating lease right-of-use assets | 20,488 | 22,791 | ||||||
| Property and equipment, net | 14,754 | 18,575 | ||||||
| Restricted cash | 524 | 524 | ||||||
| Other assets | 4,097 | 8,281 | ||||||
| Total assets | $ | 296,083 | $ | 366,597 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 5,611 | $ | 4,621 | ||||
| Accrued expenses | 7,135 | 7,937 | ||||||
| Deferred revenue | 341 | 408 | ||||||
| Operating lease liabilities, current | 2,575 | 2,312 | ||||||
| Other current liabilities | 29 | 50 | ||||||
| Total current liabilities | 15,691 | 15,328 | ||||||
| Operating lease liabilities, net of current portion | 21,077 | 23,652 | ||||||
| Other noncurrent liabilities | 8 | 48 | ||||||
| Total liabilities | 36,776 | 39,028 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, December 31, 2025 and 2024; zero shares issued and outstanding as of December 31, 2025 and 2024 | — | — | ||||||
| Class A common stock, as of December 31, 2025 and 2024; 56,219,599 and 55,083,123 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1 | 1 | ||||||
| Class B common stock, authorized as of December 31, 2025 and 2024, respectively; zero and 4,044,969 shares issued and outstanding as of December 31, 2025 and 2024, respectively | — | — | ||||||
| Additional paid-in capital | 724,819 | 719,804 | ||||||
| Accumulated other comprehensive gain | 459 | 136 | ||||||
| Accumulated deficit | (465,972 | ) | (392,372 | ) | ||||
| Total stockholders’ equity | 259,307 | 327,569 | ||||||
| Total liabilities and stockholders’ equity | $ | 296,083 | $ | 366,597 | ||||
FAQ
What were Seer (SEER) fourth-quarter 2025 revenue and gross margin?
How did Seer (SEER) perform for full year 2025 in revenue and net loss?
How many Proteograph instruments did Seer (SEER) have installed by December 31, 2025?
What cash position did Seer (SEER) report at the end of 2025?
What is Seer (SEER) revenue guidance for full year 2026 and its growth implication?
What drove Seer (SEER) operating expense changes in 2025?
